These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15358012)

  • 1. Cardiovascular therapies and risk for development of diabetes.
    Pepine CJ; Cooper-Dehoff RM
    J Am Coll Cardiol; 2004 Aug; 44(3):509-12. PubMed ID: 15358012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
    Kuti EL; Baker WL; White CM
    Curr Med Res Opin; 2007 Jun; 23(6):1239-44. PubMed ID: 17559720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of renin blockers in the prevention of diabetes.
    Alkhenizan AH; Alswes MA
    Saudi Med J; 2007 Jan; 28(1):91-5. PubMed ID: 17206297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of antihypertensive therapy.
    Grossman E; Messerli FH
    Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk, drugs and erectile function--a systematic analysis.
    Baumhäkel M; Schlimmer N; Kratz M; Hackett G; Jackson G; Böhm M
    Int J Clin Pract; 2011 Mar; 65(3):289-98. PubMed ID: 21314866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the nurses' health study.
    Michels KB; Rosner BA; Walker AM; Stampfer MJ; Manson JE; Colditz GA; Hennekens CH; Willett WC
    Cancer; 1998 Nov; 83(9):2003-7. PubMed ID: 9806660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Old or new antihypertensives--which are better?].
    Schrader J; Kulschewski A
    MMW Fortschr Med; 2005 Mar; 147(13):36-7, 39-40. PubMed ID: 15832760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of antihypertensive drugs on glucose metabolism and cardiovascular events].
    Landmark K; Reikvam A
    Tidsskr Nor Laegeforen; 2009 Sep; 129(17):1740-4. PubMed ID: 19756054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials.
    Tocci G; Paneni F; Palano F; Sciarretta S; Ferrucci A; Kurtz T; Mancia G; Volpe M
    Am J Hypertens; 2011 May; 24(5):582-90. PubMed ID: 21331058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing hypertension using combination therapy.
    Frank J
    Am Fam Physician; 2008 May; 77(9):1279-86. PubMed ID: 18540493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
    G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The management of the diabetic patient with prior cardiovascular events.
    Fonarow GC
    Rev Cardiovasc Med; 2003; 4 Suppl 6():S38-49. PubMed ID: 14668702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic advances in long-term heart failure management.
    Pfeffer MA
    Am Heart Hosp J; 2004; 2(4 Suppl 1):15-20. PubMed ID: 15539971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
    McCall KL; Craddock D; Edwards K
    Pharmacotherapy; 2006 Sep; 26(9):1297-306. PubMed ID: 16945052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 2 diabetes mellitus and heart failure.
    Choy CK; Rodgers JE; Nappi JM; Haines ST
    Pharmacotherapy; 2008 Feb; 28(2):170-92. PubMed ID: 18225964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M; Tocci G; Sciarretta S; Verdecchia P; Trimarco B; Mancia G
    J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diabetes prevention in hypertensive patients].
    Girerd X; Hansel B; Villeneuve F; Dourmap C
    Arch Mal Coeur Vaiss; 2007 Feb; 100(2):139-43. PubMed ID: 17474500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interview with Prof. Peter Dominiak, Lübeck. "Risk of diabetes with antihypertensive drugs is clinically relevant" (interview by Dr. Angelika Bischoff)].
    Dominiak P
    MMW Fortschr Med; 2004 Dec; 146(51-52):51. PubMed ID: 15675248
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hypertension therapy in practice test. Calcium antagonist receives good marks].
    Keck M; Sauerbrey-Wullkopf N; Regourd E; Clemens A
    MMW Fortschr Med; 2005 Jan; 147(1-2):51. PubMed ID: 15704573
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Lyle PA; Tershakovec AM; Devereux RB; Oparil S; Dahlöf B; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Wedel H
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):729-45. PubMed ID: 16262560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.